Clinical Pearls for the Care of Patients on Cancer Immunotherapy

Download this slideset with insights for nurses and pharmacists on managing immune-related adverse events in special patient populations, treating steroid-refractory events, identifying the etiology of toxicity with ICI combination therapies, and delivering oncology care during COVID-19.
Stephanie Andrews, MS, ANP-BC
Format: Microsoft PowerPoint (.ppt)
File Size: 459 KB
Released: May 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: September 23, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue